In Vitro Characterization of CD19 CAR T Cells Derived by Electroporation of mRNA

ASGCT 2022 -- Cancer immunotherapies reprogram the patient's immune system to mount a coordinated response against a malignant target. T cells engineered to express Chimeric Antigen Receptors (CARs) represent an effective strategy to target specific cancer cells. Electroporation of mRNA offers several advantages over viral engineering including transient expression of CAR that may limit toxicity, reduce costs associated with viral vector manufacturing and eliminate the risk of virus-associated tumorigenicity. Here, mRNA encoding an anti-CD19 CAR was electroporated into healthy, human T cells using a MaxCyte ATx® instrument.

Copy and paste this URL:

https://pub-stage.drugdevelopment.labcorp.com/latest-thinking/explore-library/detail.html/covance/assetLibrary/posters/In-vitro-characterization-CD19-CAR-T-cells-ASGCT22-Cameron.pdf